Article
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting
ARIAD Pharmaceuticals, Inc today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.
PRESS RELEASE
ARIAD Pharmaceuticals, Inc today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.
Listed below are the details of presentations at AACR that describe ARIAD’s product candidates or research programs. There will be three presentations of data on ARIAD’s investigational targeted therapies, ponatinib and AP26113; and one presentation of work on choline kinase, a discovery program which is not being pursued further at this time. Each presentation is currently available in abstract form:
Title: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1
Date & Time: Sunday, April 1, 1:00—5:00 p.m. (Poster)
Abstract: #853
Location: Hall F, Poster Section 32
Title: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
Date & Time: Monday, April 2, 8:00 a.m.—12:00 p.m. (Poster)
Abstract: #1794
Location: Hall F, Poster Section 29
Title: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib
Date & Time: Monday, April 2, 1:00—5:00 p.m. (Poster)
Abstract: #2832
Location: Hall F, Poster Section 32
Title: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells
Date & Time: Tuesday, April 3, 8:00 a.m.—12:00 p.m. (Poster)
Abstract: #3236
Location: Hall F, Poster Section 9
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow us on Twitter.
Source: ARIAD Pharmaceuticals, Inc.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
